Compare Aurora Cannabis Inc (ACB) vs MasTec Inc (MTZ) Price & Performance

Aurora Cannabis (ACB) trades at $2.99, up 0.34% with a bullish technical signal despite mixed earnings. The company achieved record annual medical cannabis revenue growth of 18% YoY to $288.6 million in FY2026, but faces margin pressure from Canadian reimbursement changes. Recent Q1 2027 earnings beat expectations with $0.04 EPS versus -$0.13 estimate, though revenue declined to $67.6 million. The stock shows strong institutional support with shareholder approval of board measures and EU-GMP certification for international expansion.

ACB presents a high-risk opportunity with significant volatility. While international medical cannabis growth and operational improvements provide upside potential, persistent net losses, negative ROE/ROA, and Canadian market challenges create substantial headwinds. Analyst consensus remains cautious with only 21% buy ratings, reflecting concerns about profitability timeline and competitive pressures in the evolving cannabis sector.

MasTec (MTZ) trades at $272.46, up 5.35% with strong YTD performance of 25.9%, outperforming the S&P 500. The stock shows bearish technical signals but maintains robust fundamentals with record Q2 2026 revenue of $4.37B and 40% EBITDA growth. Recent acquisition of The Superior Group for $1.65B expands critical infrastructure capabilities. The company raised 2026 guidance citing strong infrastructure demand and a record $21.4B backlog.

Despite technical weakness, MasTec's strong earnings momentum and 88.9% analyst buy rating with $447.91 price target suggest significant upside. Key risks include execution of large acquisitions and communications segment delays. The stock offers exposure to infrastructure growth trends but faces near-term technical headwinds.